Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) – Equities research analysts at William Blair issued their Q3 2017 earnings per share (EPS) estimates for Biohaven Pharmaceutical Holding Co in a report released on Monday. William Blair analyst T. Lugo expects that the company will post earnings per share of ($1.58) for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Biohaven Pharmaceutical Holding Co’s Q4 2017 earnings at ($1.87) EPS, FY2017 earnings at ($6.97) EPS, FY2018 earnings at ($6.41) EPS, FY2019 earnings at ($6.97) EPS and FY2020 earnings at ($4.64) EPS.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/04/research-analysts-issue-forecasts-for-biohaven-pharmaceutical-holding-co-ltds-q3-2017-earnings-bhvn.html.

Other analysts also recently issued research reports about the company. Needham & Company LLC dropped their price target on Biohaven Pharmaceutical Holding Co from $43.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday. Morgan Stanley reissued an “overweight” rating and issued a $38.00 price objective (down from $47.00) on shares of Biohaven Pharmaceutical Holding Co in a report on Tuesday. BidaskClub upgraded Biohaven Pharmaceutical Holding Co from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 28th. Piper Jaffray Companies restated a “buy” rating and issued a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, September 12th. Finally, Zacks Investment Research raised Biohaven Pharmaceutical Holding Co from a “sell” rating to a “hold” rating in a report on Tuesday, August 22nd. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $40.80.

Shares of Biohaven Pharmaceutical Holding Co (BHVN) opened at 33.08 on Wednesday. Biohaven Pharmaceutical Holding Co has a one year low of $17.00 and a one year high of $39.51. The stock’s market capitalization is $1.19 billion. The firm’s 50-day moving average is $35.38 and its 200-day moving average is $27.66.

Biohaven Pharmaceutical Holding Co Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.